Prevalence and Clinicopathologic Features of HER2 Overexpression in Endocervical Adenocarcinoma

QR Code

Prevalence and Clinicopathologic Features of HER2 Overexpression in Endocervical Adenocarcinoma

Background: Endocervical adenocarcinoma (ENCA) has poor prognosis and is increasing in developing countries. Human epidermal growth factor receptor 2 (HER2) overexpression in ENCA is not fully known. The aim of this study was to assess the prevalence and clinicopathological features of HER2 overexpr...

Full description

Saved in:

Bibliographic Details
Main Authors:	Niusha Momeni, Fatemeh Nili, Fereshteh Ameli, Soheila Sarmadi, Elham Mirzaian, Farnaz Moravej-Salehi, Narges Zamani
Format:	Article
Language:	English
Published:	Shiraz University of Medical Sciences 2025-07-01
Series:	Middle East Journal of Cancer
Subjects:	uterine cervical neoplasms her2 protein immunohistochemistry prognosis
Online Access:	https://mejc.sums.ac.ir/article_50530_0da249673a43159d98b69cd973ead445.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Complete response to trastuzumab-deruxtecan (Enhertu, T-DXd) in HER2-positive stage IVB uterine carcinosarcoma
by: Michael Kim, et al.
Published: (2025-08-01)

Clinicopathological Profile Of Her2 Positive (Non-Luminal) Breast Cancer Subtype At Haji Adam Malik General Hospital From 2020-2021
by: Yosua Natanael, et al.
Published: (2024-01-01)

Cáncer de mama HER2-bajo: una nueva era en terapias dirigidas
by: Benjamín Walbaum, MD, et al.
Published: (2025-05-01)

Developing a predictive model for neoadjuvant therapy in HER2 overexpression breast cancer using multi-parameter MRI radiomics: two-center retrospective study
by: Lingling Wang, et al.
Published: (2025-07-01)

STUDY OF THE EFFECT OF LOMUSTIN ON HER2-POSITIVE BREAST CANCER IN FVB/N HER-2 TRANSGENIC MICE
by: A. N. Stukov, et al.
Published: (2019-11-01)

Purine–Hydrazone Scaffolds as Potential Dual EGFR/HER2 Inhibitors
by: Fatemah S. Albalawi, et al.
Published: (2025-07-01)

Improving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade
by: V. F. Semiglazov, et al.
Published: (2024-11-01)

Target therapy in treatment of HER2-positive breast cancer
by: A. S. Belokhvostova, et al.
Published: (2016-02-01)

Immunomorphological specifcity of HER2-low breast cancer
by: I. V. Mikhailov, et al.
Published: (2024-11-01)

Clinicopathological Characteristics of HER2-Positive Breast Cancer Patients with BRCA1/2 Pathogenic Variants and Their Response to Neoadjuvant Targeted Therapy
by: Xingyu LIAO, et al.
Published: (2025-06-01)

Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2+ gastric cancer
by: Abbey Zidel, et al.
Published: (2025-05-01)

Current approaches to the treatment of HER2‑positive breast cancer with brain metastases
by: T. Yu. Semiglazova, et al.
Published: (2021-06-01)

Assessing functional suitability of a lyophilized formulation containing designed ankyrin repeat proteins for radionuclide imaging of HER2/neu overexpression in malignant tumors
by: R. N. Varvashenya, et al.
Published: (2024-10-01)

The development of a highly specific radiochemical compound based on labeled 99mtc recombinant molecules for targeted imaging of cells with the overexpression of Her-2 / neu
by: Olga D. Bragina, et al.
Published: (2017-10-01)

A novel bispecific aptamer targeting LAG3 and HER2 enhances T cell-mediated immunotherapy against HER2-positive cancer cells
by: Rui Guo, et al.
Published: (2025-07-01)

Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial
by: Mark Hensley, et al.
Published: (2025-07-01)

CLINICAL CHARACTERISTICS OF BREAST CANCER WITH STEROID RECEPTORS EXPRESSION AND HER2 AMPLIFICATION
by: F. V. Moiseenko, et al.
Published: (2017-02-01)

EXPERIENCE OF USING PERTUZUMAB IN ANTICANCER THERAPY FOR HER2-POSITIVE BREAST CANCER
by: O. I. Kit, et al.
Published: (2021-05-01)

EVALUATION OF EXTENT OF BREAST CANCER IN A PATIENT WITH HER2/NEU OVEREXPRESSION USING A RADIOPHARMACEUTICAL BASED ON TECHNETIUM-99M-LABELED TARGET MOLECULES (CASE REPORT)
by: O. D. Bragina, et al.
Published: (2021-10-01)

Cutaneous Granular Cell Tumor in a Middle-aged Woman: Clinicopathological Insights from a Rare Schwannian Neoplasm
by: Seetu Palo, et al.
Published: (2025-04-01)

HER2 Reactivity Pattern and Association with Various Tumor Factors in Breast Cancer Patients
by: Greeshma Ann George, et al.
Published: (2025-04-01)

STUDI IN SILICO KOMPLEKS LIGAND-RESEPTOR EUGENOL DAUN BASIL (Ocimum basilicum L.) DENGAN RESEPTOR HER2 PADA NON-SMALL CELL LUNG CANCER (NSCLC) DENGAN KONTROL GEFITINIB
by: Martina Kurnia Rohmah
Published: (2017-09-01)

HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) IN GASTRIC CANCER (GC) (RESULTS OF THE MULTICENTER CLINICAL TRIAL)
by: H. C. Chung, et al.
Published: (2017-02-01)

Polyethyleneimine-polyethylene glycol copolymer targeted by anti-HER2 nanobody for specific delivery of transcriptionally targeted tBid containing construct
by: Batoul Saqafi, et al.
Published: (2019-12-01)

Trastuzumab deruxtecan for the late lines of treatment for HER2-low metastatic breast cancer: a clinical case
by: R. A. Murashko, et al.
Published: (2025-03-01)

Achievement of complete morphological regression in the use of trastuzumab in patients with inoperable locally advanced Her-2+ breast cancer
by: K. R. Zeinalova, et al.
Published: (2014-07-01)

Silver Jubilee of HER2 targeting: a clinical success in breast cancer
by: Jianli Zhao, et al.
Published: (2025-08-01)

HER2-low Breast Cancer: Salivary Metabolic Features and Therapeutic Perspectives
by: Lyudmila V. Bel’skaya
Published: (2025-06-01)

Study of CDX2 and E-cadherin Expression in Colorectal Cancer and their Association with Clinicopathological Parameters: A Cohort Study
by: Surendran Dhanasree Vellikal, et al.
Published: (2025-07-01)

<sup>89</sup>Zr-Radiolabelling of p-NCS-Bz-DFO-Anti-HER2 Affibody Immunoconjugate: Characterization and Assessment of In Vitro Potential in HER2-Positive Breast Cancer Imaging
by: Maria-Roxana Tudoroiu-Cornoiu, et al.
Published: (2025-06-01)

NGS coverage accurately predicts MET and HER2 (ERBB2) gene amplifications in a real-world non-small cell lung cancer cohort
by: Adam Kowalewski, et al.
Published: (2025-07-01)

Key studies that have changed the history and treatment of early HER2+ breast cancer: focus on individual therapy
by: I. V. Kolyadina, et al.
Published: (2021-01-01)

Long-term survival after multidisciplinary treatments for HER2-positive advanced gastric cancer with multiple liver and lung metastases
by: Satoshi Yoshioka, et al.
Published: (2023-08-01)

HER-2-positive metastatic breast cancer: new possibilities for therapy
by: E. V. Artamonova, et al.
Published: (2014-07-01)

Endocervical adenocarcinomas. Cytological, histological, and molecular diagnostics
by: O. G. Grigoruk, et al.
Published: (2022-09-01)

Clinicopathological features of gestation course associated with uterine scar dehiscence in women with a past medical history of a single caesarean section
by: M. B. Igitova, et al.
Published: (2023-09-01)

Targeting PGK1 as a Novel strategy to regulate the sensitivity of HER2 positive gastric cancer to lapatinib
by: Xiaochen Ni, et al.
Published: (2025-07-01)

Biomarkers of the type of recurrent uterine myoma-associated growth
by: E. V. Bashirov, et al.
Published: (2021-12-01)

Successful subtotal gastrectomy and hepatectomy for HER2-positive gastric cancer with liver metastasis after trastuzumab-based chemotherapy: a case report
by: Yuki Hirase, et al.
Published: (2024-03-01)

Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins
by: O. D. Bragina, et al.
Published: (2022-10-01)